GHK-Cus pro-collagen signaling directly targets this mechanism
Recent FDA Guidance on Compounded GLP-1s: In October 2023, the FDA issued warnings about compounded GLP-1 medications, specifically cautioning patients to ensure theyre receiving semaglutide (the actual FDA-approved ingredient) rather than semaglutide salts, which have different properties
Research into GLP-1s is developing, with new information on their efficacy, side effects, and safety being published regularly
Now that the FDA has reached a decision, telehealth companies, online pharmacies, and wellness spas that have been hawking compounded tirzepatide will need to stop selling them
Mancina, Federica Tavaglione, Oveis Jamialahmadi, Umberto Vespasiani-Gentilucci, Asha Kar, Zitian Wang, Dorota Kaminska, Minna U
Based on the literature available, most test subjects have no side effects, and those that do usually have minor side effects